Antibacterial Resistance Leadership Group

**Who We Are** The Antibacterial Resistance Leadership Group (ARLG) consists of more than 100 leading experts working together to combat the antibacterial resistance crisis and improve patient care. We accomplish this goal through a [scientific agenda](https://arlg.org/about-the-arlg/arlg-scientific-agenda) that prioritizes areas of unmet needs, innovates clinical trial design, and informs practice-changing guidelines. Created in 2013, ARLG receives its funding from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health. It is facilitated by the Duke Clinical Research Institute and works under the [thought leadership](https://arlg.org/thought-leadership) of an executive committee, four component centers, and two principal investigators: Vance Fowler, MD, of Duke University, and Henry “Chip” Chambers, MD, of University of California, San Francisco. To PRIORITIZE, DESIGN, and EXECUTE clinical research that will impact the prevention, diagnosis, and treatment of infections caused by antibiotic-resistant bacteria. **KNOWLEDGEABLE** Published more than 155 manuscripts with more than 300 co-authors **CAPABLE** Initiated more than 55 studies at 130 clinical trials sites **WORLDWIDE** Collaborations in 19 countries with more than 21,000 participants